A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Pharmacokinetics of KBP-5074 in Patients With Moderate-to-Severe Chronic Kidney Disease and Uncontrolled Hypertension
Latest Information Update: 25 Mar 2024
At a glance
- Drugs Ocedurenone (Primary)
- Indications Renal hypertension
- Focus Therapeutic Use
- Acronyms BLOCKCKD
- Sponsors KBP Biosciences
- 20 Jul 2023 Results of subgroup Analysis of the BLOCK-CKD Study assessing efficacy and safety of Ocedurenone published in the American Journal of Hypertension
- 07 Nov 2022 Results of subgroup analysis evaluating Effect of Ocedurenone in Patients With Uncontrolled Hypertension and Stage 3b/4 Chronic Kidney Disease , presented at the American Heart Association Scientific Sessions 2022.
- 30 Aug 2021 Status changed from active, no longer recruiting to completed.